Constant Therapeutics, a private biopharmaceutical company, is testing its peptide drug, TXA127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7) in a phase two clinical trial at Columbia University Irving Medical Center in New York, New York, it was reported on Wednesday.
The company is enrolling 100 patients with COVID-19 who require oxygen but are not in intensive care for the double-blind, placebo-controlled trial. The product is a Mas receptor agonist and it has been indicated in various animal models of lung injury to decrease inflammation, stabilise endothelial and epithelial barriers and decrease fibrosis.
The endpoints of the trial include incidence of renal failure and incidence of respiratory failure.
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
ACG to invest USD200m in US hard-shell capsule manufacturing